This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Applications of synthetic biology in medical and pharmaceutical fields
Signal Transduction and Targeted Therapy Open Access 11 May 2023
-
CAR T cells: engineered immune cells to treat brain cancers and beyond
Molecular Cancer Open Access 31 January 2023
-
Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses
World Journal of Surgical Oncology Open Access 13 January 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
PowerPoint slides
Rights and permissions
About this article
Cite this article
Yip, A., Webster, R. The market for chimeric antigen receptor T cell therapies. Nat Rev Drug Discov 17, 161–162 (2018). https://doi.org/10.1038/nrd.2017.266
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.266
This article is cited by
-
CAR T cells: engineered immune cells to treat brain cancers and beyond
Molecular Cancer (2023)
-
Targeted modulation of immune cells and tissues using engineered biomaterials
Nature Reviews Bioengineering (2023)
-
Applications of synthetic biology in medical and pharmaceutical fields
Signal Transduction and Targeted Therapy (2023)
-
Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses
World Journal of Surgical Oncology (2022)
-
Engineered cells as glioblastoma therapeutics
Cancer Gene Therapy (2022)